Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Healthy Adults 18-49 Years of Age
Brief Summary: This Phase 3 study is intended to assess the clinical lot-to-lot consistency in manufacturing by evaluating and comparing the immunogenicity of three consecutively manufactured lots of the Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine, during the 2016-2017 influenza season, in healthy adults 18-49 years of age. A single dose of one of three consecutive lots of Quadrivalent VLP Influenza Vaccine (30 µg/strain) will be administered to 1,200 participants.


Options:
A: Arm Label: Quadrivalent VLP Influenza Vaccine - Lot 1; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent VLP Influenza Vaccine | Arm Label: Quadrivalent VLP Influenza Vaccine - Lot 2; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent VLP Influenza Vaccine | Arm Label: Quadrivalent VLP Influenza Vaccine - Lot 3; Type: EXPERIMENTAL; Interventions: Biological: Quadrivalent VLP Influenza Vaccine | Intervention Type: BIOLOGICAL; Name: Quadrivalent VLP Influenza Vaccine; Assigned to Arm(s): Quadrivalent VLP Influenza Vaccine - Lot 1, Quadrivalent VLP Influenza Vaccine - Lot 2, Quadrivalent VLP Influenza Vaccine - Lot 3
B: Arm Label: mRNA-1273; Type: EXPERIMENTAL; Interventions: Biological: mRNA-1273 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: mRNA-1273 BD; Type: EXPERIMENTAL; Interventions: Biological: mRNA-1273 | Arm Label: mRNA-1273.222; Type: EXPERIMENTAL; Interventions: Biological: mRNA-1273.222 | Intervention Type: BIOLOGICAL; Name: mRNA-1273; Assigned to Arm(s): mRNA-1273, mRNA-1273 BD | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: mRNA-1273.222; Assigned to Arm(s): mRNA-1273.222
C: Arm Label: Low dosage vaccine on a 0- and 28-day schedule; Type: EXPERIMENTAL; Interventions: Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule | Arm Label: Low dosage vaccine on a 0- and 14-day schedule; Type: EXPERIMENTAL; Interventions: Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule | Arm Label: Medium dosage vaccine on a 0- and 28-day schedule; Type: EXPERIMENTAL; Interventions: Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule | Arm Label: Medium dosage vaccine on a 0- and 14-day schedule; Type: EXPERIMENTAL; Interventions: Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule | Arm Label: High dosage vaccine on a 0- and 28-day schedule; Type: EXPERIMENTAL; Interventions: Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule | Arm Label: High dosage vaccine on a 0- and 14-day schedule; Type: EXPERIMENTAL; Interventions: Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule | Arm Label: Placebo on a 0- and 28-day schedule; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo on a 0- and 28-day schedule | Arm Label: Placebo on a 0- and 14-day schedule; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo on a 0- and 14-day schedule | Intervention Type: BIOLOGICAL; Name: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Assigned to Arm(s): Low dosage vaccine on a 0- and 28-day schedule | Intervention Type: BIOLOGICAL; Name: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Assigned to Arm(s): Low dosage vaccine on a 0- and 14-day schedule | Intervention Type: BIOLOGICAL; Name: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Assigned to Arm(s): Medium dosage vaccine on a 0- and 28-day schedule | Intervention Type: BIOLOGICAL; Name: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Assigned to Arm(s): Medium dosage vaccine on a 0- and 14-day schedule | Intervention Type: BIOLOGICAL; Name: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule; Assigned to Arm(s): High dosage vaccine on a 0- and 28-day schedule | Intervention Type: BIOLOGICAL; Name: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule; Assigned to Arm(s): High dosage vaccine on a 0- and 14-day schedule | Intervention Type: BIOLOGICAL; Name: Placebo on a 0- and 28-day schedule; Assigned to Arm(s): Placebo on a 0- and 28-day schedule | Intervention Type: BIOLOGICAL; Name: Placebo on a 0- and 14-day schedule; Assigned to Arm(s): Placebo on a 0- and 14-day schedule
D: Arm Label: Placebo - Phase 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal saline solution (NSS), Placebo - Phase 1 | Arm Label: SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 rS - Phase 1 | Arm Label: SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 | Arm Label: SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 | Arm Label: SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Other: Normal saline solution (NSS), Placebo, Day 21 - Phase 1 | Arm Label: Placebo - Phase 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal saline solution (NSS), Placebo - Phase 2 | Arm Label: SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2; Type: EXPERIMENTAL; Interventions: Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 | Arm Label: SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2; Type: EXPERIMENTAL; Interventions: Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 | Arm Label: SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2; Type: EXPERIMENTAL; Interventions: Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 | Arm Label: SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2; Type: EXPERIMENTAL; Interventions: Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 | Arm Label: SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2; Type: EXPERIMENTAL; Interventions: Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 | Arm Label: SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2; Type: EXPERIMENTAL; Interventions: Other: Normal saline solution (NSS), Placebo - Phase 2, Biological: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2 | Intervention Type: BIOLOGICAL; Name: SARS-CoV-2 rS - Phase 1; Assigned to Arm(s): SARS-CoV-2 rS - 25 μg without Matrix-M - Phase 1 | Intervention Type: BIOLOGICAL; Name: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1; Assigned to Arm(s): SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 1, SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 1 | Intervention Type: OTHER; Name: Normal saline solution (NSS), Placebo - Phase 1; Assigned to Arm(s): Placebo - Phase 1 | Intervention Type: OTHER; Name: Normal saline solution (NSS), Placebo - Phase 2; Assigned to Arm(s): Placebo - Phase 2, SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2 | Intervention Type: BIOLOGICAL; Name: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1; Assigned to Arm(s): SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1 | Intervention Type: OTHER; Name: Normal saline solution (NSS), Placebo, Day 21 - Phase 1; Assigned to Arm(s): SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M then Placebo - Phase 1 | Intervention Type: BIOLOGICAL; Name: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2; Assigned to Arm(s): SARS-CoV-2 rS - 25 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - 25/25 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - 5 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - 5/5 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - 5/5/5 μg + 50 μg Matrix-M - Phase 2, SARS-CoV-2 rS - Alternating 5/5 μg + 50 μg Matrix-M - Phase 2

Answer: A